References to individual volumes are listed before colons; numbers following a colon refer to page numbers. A **boldface** page number indicates the main essay for a topic. An *italicized* page number refers to a photo or illustration.
impulse-control disorders and, 1:523
inhalant, 1:525, 526, 527, 528, 529
Internet, 1:537–539
interpersonal therapy for, 1:540
lorazepam, 1:574
mirtazapine for, 2:641
neurotransmitters and, 1:296, 2:659
nicotine, 2:661, 663, 952
opioid, 2:696, 697, 698, 699–700
panic disorder and, 2:719
pemoline, 2:745
phencyclidine, 2:755
polysubstance, 1:299, 2:770–771
process of, 1:296, 537
relapse, 2:819, 821
recovery systems and, 1:296
schizophrenia and, 2:849
sleep terror disorder in, 2:902
suicide by, 2:586
process of, 1:296, 537
stress and, 1:21, 22–23, 24, 2:940
Adler, Alfred, 1:468, 2:709
Adlerian therapy, 2:647
Adolescents
addiction and, 1:20
adjustment disorder in, 1:23–24
aggression in, 2:985
anorexia nervosa in, 1:59–60
anorexia nervosa in, 1:60–64
antidepressants for, 1:542–543
Asperger’s disorder and, 1:84
autism and, 1:102
body dysmorphic disorder in, 1:134, 135
bulimia nervosa and, 1:154, 155, 159–160
bupropion for, 2:746
cannabis and, 1:171–172, 173
case management for, 1:177
cigarette smoking by, 2:662–663
cocaine and, 1:218
conduct disorder in, 1:237
cyclothymic disorder in, 1:261
depression in, 1:185
with dual diagnosis, 1:339
explosive behavior in, 2:985
family education and, 1:394
intelligence tests for, 1:553–555, 2:1030
interpersonal therapy for, 1:542–543
Kaufman Short Neurological Assessment Procedure for, 1:556–558
major depressive disorder in, 2:583, 586
multisystemic therapy for, 2:636–640
neglected, 2:654
obsessive-compulsive disorder in, 2:689
oppositional defiant disorder in, 2:703
pedophilia and, 2:741
peer groups and, 2:743–745
phencyclidine and, 2:755
premature ejaculation in, 2:782
prescription drug abuse by, 1:66
psychoanalysis for, 2:791
pyromania in, 2:802–804, 805
schizotypal personality disorder in, 2:860
seasonal affective disorder in, 2:862
selective mutism in, 2:870
separation anxiety disorder in, 2:881
sleep terror disorder in, 2:902
social phobia in, 2:905–907, 908, 909–910
specific phobias in, 2:920, 925
stereotypic movement disorder in, 2:931, 932
stuttering in, 2:949
Substance Abuse Subtle Screening Inventory for, 2:954
suicidal behavior in, 2:744, 961
suicide by, 2:586
temper tantrums in, 2:985
tic disorders in, 2:985
transvestic fetishism in, 2:991
trichotillomania in, 2:999
voyeurism in, 2:1024
Adoption studies (Genetic), 1:447
Adrenal gland disorders, 2:708
Adrenalin, 2:660
Adult abuse, 1:4, 6–7
Addiction Potential Scale, 2:625
Address of a special health status, 1:20
Adjustment disorder, 1:237–238
specific phobias in, 2:920, 925
Adonis, 2:779, 923
Adonis-C (Anxiety Disorders Interview Scale), 2:779, 923
Advisors
Addiction Potential Scale, 2:625
Polysubstance, 1:299, 2:770–771
process of, 1:296, 537
relapse, 2:819, 821
reward systems and, 1:296
ADIS (Anxiety Disorders Interview Scale), 2:779, 923
ADIS-C (Anxiety Disorders Interview Scale), 2:779, 923
ADIS-C (Anxiety Disorders Interview Scale for Children), 2:908
Adjustment disorder, 1:20–24
acute stress disorder and, 1:15, 22
depression and, 2:989
post-traumatic stress disorder, 2:989
stress and, 1:21, 22–23, 24, 2:940
Advocacy, 1:547, 2:878
Aerobic exercise, 1:402
Affect, 1:25–26
assessment of, 1:92, 450
blunted, 1:26, 2:850, 855
dysthymic disorder and, 1:76, 344
histrionic personality disorder and, 1:496
Affective disorders. See Mood disorders
African Americans
Alzheimer’s disease and, 2:934
body dysmorphic disorder in, 1:135
bulimia nervosa in, 1:157
cigarette smoking by, 2:662–663
generalized anxiety disorder in, 1:437
hypertension in, 2:946
Kaufman Short Neurological Assessment Procedure and, 1:558
masculinity and, 1:433
sadness in, 2:720
specific phobias in, 2:922
stigmatization of, 2:935
stroke in, 2:945, 946, 948
Aftercare groups, 2:821
Age-associated memory impairment, 1:279, 2:655
Agent-driven directives, 1:25
Aggression
in adolescents, 2:985
Alzheimer’s disease and, 1:42
assertiveness training and, 1:88, 89
causes of, 2:709
cognitive problem-solving skills training for, 1:221
conduct disorder and, 1:237, 238, 238
Diagnostic and Statistical Manual of Mental Disorders on, 1:308
impulsive, 1:534–536
obsessive, 2:688
paranoid personality disorder and, 2:726
in peer groups, 2:743–744
pyromania and, 2:802
social phobia and, 2:907
Thematic Apperception Test for, 2:974
See also Apperception Test for
Aging
cognitive retraining for, 1:224–226
erectile dysfunction and, 1:368
fear of, 1:202
female sexual arousal disorder and, 1:410
loss and, 1:459
memory loss and, 2:939
Among
Alcoholism; Substance abuse; Twelve step programs
Adolescents
Alcohol dependence, 1:21
Alcoholism, 1:21
Among
Alcoholism; Substance abuse; Twelve step programs
Adolescents
Alcohol dependence, 1:21
Alcoholism, 1:21
narcissistic personality disorder and, 2:648
respite care and, 2:822
schizophrenia and, 2:848
stigmatization of, 2:935
support groups for, 2:965
women and, 1:433
See also Elderly

Agitation
Alzheimer's disease and, 1:42, 44
brief psychotic disorder and, 1:153
delusional disorder and, 1:272
fluphenazine for, 1:416–417
haloperidol for, 1:272
lorazepam for, 1:272
schizoaffective disorder and, 2:841
thioridazine for, 2:978
thiothixene for, 2:980–982
trifluoperazine for, 2:1001–1003

Agnosia, 1:41, 277
Agnosia, 1:41, 277

Agoraphobia, 1:26–30, 2:720
bibliotherapy for, 1:119
exposure treatment for, 1:28, 29, 382
genetic factors in, 1:26–27, 446, 2:720, 906
guided imagery for, 1:472
with panic attacks, 1:26, 228
with panic disorder, 1:26, 71, 2:717–722, 923
social phobia and, 1:26, 28, 2:906
tic disorders and, 2:997
tranylcypromine for, 2:993
treatment of, 2:721

Agoraphobic Self-Statements Questionnaire, 1:29
Agranulocytosis, 1:130, 210, 211, 2:852

AHPA (American Herbal Products Association), 1:458, 559

AIDS. See Acquired immune deficiency syndrome

Akathisia
beta blockers for, 1:117–118
from mesoridazine, 2:617
neuroleptic-induced, 2:603, 605, 606
tardive, 2:971

Akinesia, 1:180, 181, 2:636

Al-Anon. See Alcoholics Anonymous

Alateen, 2:877

Alcohol
anxiety disorder and, 2:955–957
barbiturates and, 1:110
breathing-related sleep disorder and, 1:149
cannabis and, 1:172
chloral hydrate and, 1:193
chlorpromazine and, 1:196
clozapine and, 1:204
clonazepam and, 1:206
clozapine and, 1:209
cocaine and, 1:212
counselors, 1:546
delirium and, 1:268
desipramine and, 1:295
detoxification, 1:295, 297
diazepam and, 1:310, 311
diphenhydramine and, 1:317
doxepin and, 1:338
erectile dysfunction and, 1:369
estazolam and, 1:372
fluoxetine and, 1:415
flurazepam and, 1:419
in foods, 1:315
gabapentin and, 1:423
haloperidol and, 1:482
imipramine and, 1:521, 522
insomnia and, 1:531
intermittent explosive disorder and, 1:536
kava kava and, 1:560
lorazepam and, 1:574
maprotiline and, 2:598
mesoridazine and, 2:617
methadone and, 2:619
mirtazapine and, 2:627
mollindone and, 2:634
narcolepsy and, 2:650
 nefazodone and, 2:652
 nortriptyline and, 2:669
 olanzapine and, 2:696
 oxazepam and, 2:712
 paranoa and, 2:723
 phelazine and, 2:758
 pimozide and, 2:765
 propanolol and, 2:785
 protriptyline and, 2:786, 787
 psychotic disorder from, 2:957–958
 quazepam and, 2:807, 808
 quetiapine and, 2:809
 SAMe and, 2:838
 temazepam and, 2:972, 974
 thioridazine and, 2:979
 thiothixene and, 2:982
 for tic disorders, 2:982
 tranylcypromine and, 2:994, 995
 trazodone and, 2:997
 triazolam and, 2:997
 trifluoperazine and, 2:1002
 valerian and, 2:1015
 venlafaxine and, 2:1020
 zaleplon and, 2:1045
 zolpidem and, 2:1048, 1049
See also Alcohol abuse; Alcoholism

Alcohol abuse, 1:19, 30–35
adjustment disorder and, 1:23
amnestic disorders from, 1:50, 51, 52, 2:1032, 1034
aversion therapy for, 1:104–105
biofeedback for, 1:122
chloridiazepoxide for, 1:193, 297
dementia from, 1:275, 279
denial and, 1:283
diagnosis of, 1:33, 2:899
disease model of, 1:18, 317–318
disulfiram for, 1:19, 34, 322–333
executive function and, 1:375
exposure treatment for, 1:384–385
gamma-aminobutyric acid and, 2:659
gender differences in, 1:19
histrionic personality disorder and, 1:497
mental disorders from, 2:710
mesoridazine for, 2:616–617
naltrexone for, 1:34, 2:641
neurotransmitters and, 1:18, 32, 2:659
nutrition deficiency from, 2:670, 672
person-centered therapy for, 2:751
self-help groups for, 1:34, 2:876–877
suicide and, 2:960
tic disorders from, 2:987
treatment of, 1:300, 332–333
twelve step programs for, 1:30, 299, 545, 2:876–877, 879, 963

poly-substance dependence and, 2:771
post-traumatic stress disorder and, 2:778
relapse, 2:820
social phobia and, 2:904, 906
social skills training for, 2:911, 912
in veterans, 2:778
See also Alcohol withdrawal; Alcoholism

Alcohol withdrawal, 1:31, 32, 33–34
alprazolam for, 1:35
chloridiazepoxide for, 1:193
clonidine for, 1:206–207
clorazepate for, 1:208
delirium from, 1:266, 268
diazepam for, 1:297, 309
diet and, 1:313
hallucinations from, 1:475
oxazepam for, 2:710–712
panic attacks from, 2:720
stress and, 2:940
symptoms of, 1:296–297

Alcoholics Anonymous, 1:20, 34, 299, 545, 2:876–877, 965
Alcohol-induced amnestic disorders, 1:50, 51, 52, 2:1032, 1034

Alcoholism, 1:19, 30–35
adjustment disorder and, 1:23
amnestic disorders from, 1:50, 51, 52, 2:1032, 1034
aversion therapy for, 1:104–105
biofeedback for, 1:122
chloridiazepoxide for, 1:193, 297
dementia from, 1:275, 279
denial and, 1:283
diagnosis of, 1:33, 2:899
disease model of, 1:18, 317–318
disulfiram for, 1:19, 34, 322–333
executive function and, 1:375
exposure treatment for, 1:384–385
gamma-aminobutyric acid and, 2:659
gender differences in, 1:19
histrionic personality disorder and, 1:497
mental disorders from, 2:710
mesoridazine for, 2:616–617
naltrexone for, 1:34, 2:641
neurotransmitters and, 1:18, 32, 2:659
nutrition deficiency from, 2:670, 672
person-centered therapy for, 2:751
self-help groups for, 1:34, 2:876–877
suicide and, 2:960
tic disorders from, 2:987
treatment of, 1:300, 332–333
twelve step programs for, 1:30, 299, 545, 2:876–877, 879, 963

See also Elderly